EyePoint Pharmaceuticals heads into July with a sharp analyst upgrade colliding against a short base that refuses to budge — a tension that defines the stock's setup heading into its July 31 earnings event.
The most striking development this week is the Street's newfound conviction on the upside. Chardan Capital more than doubled its price target on July 1, lifting it from $29 to $65 while maintaining its Buy rating — a move that implies roughly 355% upside from the current $14.30 price. Guggenheim reiterated its own Buy last week with a $68 target. RBC Capital, which trimmed its Outperform target from $39 to $37 back in May, is the outlier in an otherwise bullish analyst pack. The consensus mean target sits at $40 — itself nearly three times the current price — underscoring how wide the gap is between what analysts see in DURAVYU's commercial potential and what the market is currently willing to pay. The bull case rests on peak sales estimates of $2.1 billion for DURAVYU in wet AMD and diabetic macular edema, with a potential NDA filing on the horizon. Bears counter that the AMD treatment space is intensely competitive and that EyePoint's balance sheet still bleeds cash, with deeply negative EPS and an EV/EBITDA that sits at -2.5x.
The short base has not been moved by the analyst enthusiasm. Short interest is essentially flat on the week at 18.8% of the free float — roughly 15.6 million shares — and has grown about 9% over the past month. That is an elevated and slowly expanding short position despite a 5% gain in the stock over the past month. The borrow market, however, tells a different story about conviction. Cost to borrow, while up 25% on the week, remains very low in absolute terms at just 0.5%. Availability is wide at 542% of current short interest — meaning there are more than five shares available to borrow for every one already shorted. Bears are not paying a premium to hold their positions, which suggests this is a considered thesis rather than a trapped, distressed short. The ORTEX short score of 68.8 has been stable all week, confirming no dramatic shift in the underlying dynamics from the prior note.
Options traders have turned more defensive than usual, adding another layer of caution to the picture. The put/call ratio is running at 1.60, well above its 20-day average of 1.24 — approximately 1.7 standard deviations above the mean. That defensive skew has emerged in just the past week: PCR was sitting near 1.33–1.38 for most of mid-June before jumping sharply after June 22. With earnings due July 31, options buyers appear to be hedging rather than pressing upside bets, despite the bullish analyst action. Among correlated peers, HELP surged 36% on the week while OCUL fell 2.9% and TARS dropped 4.9% — a mixed peer backdrop that offers no clear sectoral tailwind for EYPT.
On the ownership side, BlackRock added 389,000 shares through May and now holds 8.6% of the company. Janus Henderson added 663,000 shares through March. Citadel entered as a new holder with a 2.3% position. Those are meaningful accumulation signals from institutional players, but they sit alongside a CFO who sold a small tranche in May following a share award — routine rather than alarming, given the $47,000 transaction value. The CEO's March open-market purchase of 1,500 shares at $13.15 remains the most recent directional signal from inside the building.
The July 31 earnings print is therefore the next hard test — the question is less whether DURAVYU's data continues to impress and more whether the company can demonstrate a credible commercial path to justify a target price structure that currently lives almost entirely in analyst models rather than in the stock.
See the live data behind this article on ORTEX.
Open EYPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
